GLP-1 | pharmaphorum

Friday 5 December 2025

GLP-1

News

Eli Lilly HQ

Lilly soars on first data for oral obesity candidate

Shares in Eli Lilly rose sharply in pre-market trading today after it reported phase 3 results for oral diabetes and weight-loss drug orforglipron.

News

Pfizer's weight-loss aspirations are dealt a heavy blow

Pfizer's weight-loss aspirations are dealt a heavy blow

Pfizer has been forced to discontinue its oral GLP-1 receptor agonist danuglipron after seeing signs of liver toxicity in late-stage clinical testing.

R&D

Endoscopy

Sponsored

Obesity and the endoscopy space: Innovative, minimally invas...

According to the World Health Organization (WHO), in 2022, 2.5 billion adults aged 18 years and older were overweight, including over 890 million adults who were living with

Market Access

Boehringer US head covers GLP-1s, PBMs, Trump at Reuters USA

Boehringer US head covers GLP-1s, PBMs, Trump at Reuters USA

Brian Hilberdink, Boehringer Ingelheim's new Head of US Human Pharma, fielded questions on a variety of hot topics from the Reuters Pharma USA stage.

Market Access

tablets and measuring tape

UK weight loss market: M&A opportunities

Recent advancements in weight-loss interventions are transforming the healthcare landscape and presenting new M&A opportunities

News

Five doses of Wegovy

Novo Nordisk follows Lilly into DTC obesity drug market

Novo Nordisk has launched direct-to-consumer sales of its obesity drug Wegovy for uninsured or under-insured people at $499 per month.